Patient information and compliance in cardiovascular disease by Saeed, Maryam & Roshan, Faryane Mohebbi
 1 
Patient information and compliance in cardiovascular disease 
 
 
 
F Roshan, M Saeed, S Agewall 
 
 
 
Division of Cardiology, Faculty of Medicine, Oslo University Hospital and Oslo University, 
Norway 
 
 
 
 
 
Corresponding author 
Professor Stefan Agewall, MD, PhD, FESC FACC 
Division of Cardiology, Faculty of Medicine, Oslo University Hospital, Oslo University 
Norway 
Phone: + 47-22 89 46 55 
Fax: + 47-22 89 47 21 
Email: stefan.agewall@medisin.uio.no 
 2 
Abstract: 
 
Background: statins are frequently used prophylactic in CHD, however adherence is 
suboptimal. We expect that comprehensive information will increase adherence in patients. 
Aims: to examine if different types of prognostic information associated with prescription of 
a certain drug by physicians can influence patients to take the drug as recommended, and to 
investigate whether patients want this type of information. 
Methods: A survey was performed in 313 patients diagnosed with CVD. Patients were 
presented to three facts with relative risk reduction and absolute risk reduction figures 
associated with the use of the drug and self-estimated likelihood of taking the drug as 
prescribed was registered after each given fact. 
Results: Self-estimated likelihood of taking the drug as prescribed was highest when the 
cardiologist recommended the drug without presenting absolute and relative risk reduction 
figures (p<0.001).  Presenting relative risk reduction figures for the patients gave significantly 
higher self-estimated likelihood to take the drug as prescribed compared to giving the patients 
absolute risk reduction figures (p<0.001). A vast majority of the patients (84%) wanted to get 
information about risk reduction associated with the drug treatment.   
Conclusion:  The patients wanted information about the CV risk reduction associated with the 
prescribed drug; however, the best self-estimated compliance was achieved when the 
cardiologist recommended the drug without presenting risk reduction figures. Realrive risk 
reduction was associated with a better compliance the absolute risk reduction figures.  
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Introduction: 
Coronary heart disease is very common worldwide. The treatment of this disease has changed 
dramatically during the last decade. A more aggressive pharmacological treatment is 
combined with revascularization of patients. All patients with acute coronary heart disease are 
now recommended treatment with statins (1-2).  
 
Despite significant increases in use of statins they are still clearly underused. (3-4) This along 
with evidence of poor adherence and discontinuation rates between 40-60% within the first 
year of statin therapy (5) contributes to the phenomenon referred to as the “treatment gap” (5-
6), which is defined as the gap between treatment recommended and the treatment that 
actually occurs. (7). This gap is significant and potentially fatal for cardiac patients. Several 
studies have shown that comprehensive information by physicians significantly improved 
adherence of statin therapy and decreased the rate of discontinuation. (8-9). Well-informed 
patients have an increased likelihood of having suggested LDL cholesterol targets (10). 
 
Less is known about how detailed this information should be. Should doctors inform the 
patients about percentage risk reduction and absolute risk reduction or should they just tell 
patients that the treatment decreases risk of a new MI? Do patients want this type of detailed 
information? 
 
The aim of our study was to examine if different types of prognostic information associated 
with prescription of a certain drug by physicians can influence patients to take the drug as 
recommended, and to investigate whether patients want this type of information.   
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Methods: 
To enlighten the aspects mentioned a survey was performed in 313 (134 female, 179 men) 
consecutive patients admitted to the cardiology unit at the department of medicine, Oslo 
university hospital Aker. The participants were enrolled in the study by giving written consent 
after receiving oral and written information. The study was approved by the ethical 
committee. 
 
All patients were asked 4 survey questions (Figure 1) by two of the authors (FR and MS). A 
standard questionnaire was used to register the patient’s self-estimated likelihood of taking 
the drug as prescribed, after introducing them to different kinds of standardized information. 
The questions were based on results from the 4S study (11). 
 
Statistical Analysis: 
Quantitative data are presented as mean  standard deviation. Differences in categorical 
parameters (survey questions) were assessed using marginal homogeneity test in StatXact 8 
(Cytel inc., 2007). All statistical tests were conducted at the 5% significance level. 
 
Results:  
The basal characteristics of the patients are presented in Table 1. All patients had a heart 
disease and were either hospitalized or visiting the cardiology outpatient unit.  
 
The survey results from question 1-3 given are presented in Figure 2. Most of the patients 
estimated that they would use the drugs as prescribed (answer alternative 1 or 2) after all three 
statements; 93% in question 1, 91% in question 2, 83% in question 3. 
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When comparing the answers from the patients; more patients estimated that they would take 
the medication as prescribed when presented to the statement related with Q1 compared to 
statements related with the other questions. (Q1 vs. Q2: p = 0.0003 and Q1 vs. Q3: p < 
0.0001). The statement linked with Q2 was associated with higher self-estimated adherence 
compared to that of Q3 (Q2 vs. Q3: p < 0.0001). 
 
84% of the patients stated that they wanted information (answer alternative 1 or 2) about the 
expected effect of the drug to be given at initiation of therapy (Q4). 9% stated “Probably not” 
and 7% stated “Absolutely not”.   
 
There were no significant differences in the answers to Q1-4 between the genders (p >0.1).  
There was neither any significant difference between the answers of Q1-3 when comparing 
younger patients with older patients ( 69 years vs 69 years). Younger patients were more 
positive to more detailed risk reduction information. In Q4, 80% of the younger patients 
answered “Yes, absolutely” in contrast to 54% of the older patients (p < 0.01).   
 
 
Discussion:  
Statins have through many studies and randomized trials demonstrated their efficacy in 
reducing mortality and morbidity in different groups of subjects, therefore they are frequently 
prescribed drugs for both primary and secondary prevention.  
 
Given the importance of prophylactic treatment with statins, a combination of under 
prescription and poor compliance is potentially fatal. The drug is only effective if the patient 
takes it. Information from physicians to patients has shown to enhance adherence. Although it 
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might be well expected that comprehensive information will give us more compliant patients, 
less is known about how patients should be informed. How much details from scientific 
studies should be included in the information? In order to increase adherence; the national 
cholesterol education program (NCEP) expert panel suggests that one should particularly 
emphasize the mortality and morbidity benefit of the statin therapy (12). There is also 
evidence that patients’ knowledge about cholesterol and the role of cholesterol modifying 
strategies should be determined prior to initiation of treatment. (9) Thus, a patient that is 
convinced of the prophylactic benefits of statins shows enhanced compliance. (13)  
 
Should doctors just prescribe a drug or should they present more underlying documentation of 
the drug? And in what way should this documentation be described? Should with give 
absolute reduction figures or percentage reduction figures? And furthermore, do the patients 
want to know these figures? 
 
Most of the patients in this study reported an overall high self-estimated likelihood of taking 
drugs as they were prescribed. This indicates that most patients have faith in medicine and 
follow physicians’ recommendation.  
 
The fact that the majority of patients wanted information about the expected outcome of a 
certain drug to be given at initiation of therapy shows a willingness to understand and 
participate in issues concerning their own health and well being. In our study a vast majority 
of the patients answered they would highly appreciate information on expected effects of 
outcome of the drug they were prescribed. Only 7% answered “Absolutely not” on whether 
they wanted outcome information about their drug therapy. 
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The results from this study showed that most of the patients responded better to an easy, 
understandable concise recommendation as given in fact 1 (Q1). This simple statement 
achieved a better self-estimated likelihood of taking the drug compared to presenting relative 
and absolute risk reduction figures for the patients. When presented to relative risk reduction 
figures, the patients reported a higher likelihood of taking the drug as prescribed than when 
they were given absolute risk reduction figures (Q2 vs Q3). This seems to be logical since 
relative risk reduction often appears to be more impressive than absolute risk reduction. 
Pharmaceutical companies and authors of large intervention studies also seem to prefer 
presenting positive results with relative risk reductions rather than absolute risk reduction.  
Some of the documentations in fact two and three were confusing to many of the patients. 
Especially fact 3 was often difficult to comprehend. The more detailed and complex the facts 
got the more critical the patients became. We registered 77% answering “Yes, absolutely” 
after Q1 compared to only 53% on Q3. This implies that specific research data may increase 
uncertainty rather than assuring the patients of the benefits of the drug prescribed. In this 
matter the answers from the patients proved to be similar in both genders and in both age 
groups as well. This was interesting since many of the older patients impulsively mentioned 
that they did not expect to live another 5 years when answering the questions.  
 
Whether a specific gender or high age is a factor of non-compliance or the opposite remains 
unclear because different studies have produced conflicting results. One study showed that 
compliance was lower with high age (14), while another study has found that those who stated 
to use statins continuously were older than those who stated not (10). Female gender has 
proven to be an independent factor of non-adherence in a study (15). 
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However a discrepancy was seen between the answers to the question regarding whether or 
not the patients wanted information about the expected outcome of the drug to be given at 
initiation of therapy (Q4). Significantly more of the younger patients wanted this type of 
information compared to the older group.   
 
We do believe the patients are representative for patients seen at a hospital based cardiology 
unit. From our study we can conclude that relative reduction figures gave higher self-
estimated likelihood of taking drugs as prescribed compared to the absolute risk reduction 
figures. It seemed as specific research data increased uncertainty rather than assuring the 
patients of the benefits of the drug prescribed. Therefore it might be appropriate to say that 
physicians that strive to increase adherence, should present the patients to easy, 
comprehensive reduction figures opposed to more detailed and complex reduction figures. 
This was supported by the fact that the highest self-estimated likelihood for taking the drug 
was achieved after a distinct recommendation from the cardiologist. 
 
An expected bias in our study may be that the self-estimated likelihood of adherence very 
well may differ from the actual adherence in patients. The compliance rate may be 
overestimated when this method is used. Furthermore the authors were frequently asked 
questions about the reputes of the physician prescribing the drugs, possible side-effects, 
alternatives to the drug and the need and reason behind getting it prescribed. These are all 
factors that are liable of influencing the adherence, but our study does not take these factors in 
consideration.   
 
We conclude that most patients in a cardiology unit want detailed information about the 
expected outcome associated with a certain drug. However, most of the patients reported a 
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higher self-estimated likelihood of taking the drug as prescribed with an easy, understandable 
concise recommendation compared to providing them with relative and absolute risk 
reductions figures. 
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Table 1: Patient characteristics (n=313) 
 
Gender 
Female (n=134) 
Male (n=179) 
 
43% 
57% 
Age (years) 69 14 
Main Diagnosis 
AMI (n=109) 
Heart Failure (n=44) 
Arrhythmia (n=96) 
Angina (n=32) 
Valvular Defect (n=32) 
 
35% 
14% 
31% 
10% 
10% 
BP (mm Hg) 
Systolic BP 
Diastolic BP 
 
139±21 
79±13 
Heart Rate (BPM) 76±21 
S-chol (mmol/l) 4,4±1,3 
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Figure 1: 
Questionnaire:  
Introduction: 
A study on the effects of statins as prophylactic treatment for CHD gives the following 
information: 
 
Fact 1: Your cardiologist recommends this medication, which reduces the risk of AMI. 
Q1: Will this information lead you to use the medication as prescribed? 
Fact 2: Within a period of 5 years; this medication reduces the risk of death caused by heart 
disease by 42% and the risk of AMI by 34%. 
Q2: Will this information lead you to use the medication as prescribed? 
Fact 3: Without this medication 88% of the patients will still be alive after 5 years. Of those 
using the medication 91% will survive. The risk of AMI is 20% if one uses the medication, but 
29% for those not using the medication. 
Q3: Will this information lead you to use the medication as prescribed? 
 
Should this type of information be given to patients at initiation of treatment? 
Q4: Cross out the answer that fits you best. 
All the questions had the following answer alternatives: 
 
1. Yes, absolutely 
2. Yes, probably 
3. Probably not 
4. Absolutely not 
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Figure 2: 
 
 
 
 
 
Legends 
Survey results from question 1-3 
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